Nov 25, 2024 08:23AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Oct 10, 2024 07:56AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Aug 30, 2024 08:21AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) following HELIOS-B readout

Aug 27, 2024 07:47AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Aug 13, 2024 10:01AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Jul 16, 2024 05:50AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Jun 24, 2024 07:52AM BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data

Apr 8, 2024 09:50AM BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)

Feb 13, 2024 05:35AM BMO Capital Pounds Table on Silence Therapeutics (SLN), New Top Pick

Feb 11, 2022 07:21AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $175 at BMO Capital

Jan 25, 2021 12:37AM UPDATE: BMO Capital Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform

Nov 24, 2020 11:38AM Alnylam Pharmaceuticals (ALNY) PT Raised to $183 at BMO Capital

Nov 20, 2019 04:41PM Alnylam (ALNY) PT Raised to $138 at BMO Capital Following Givlaari Early Approval With Favorable Label

May 1, 2019 12:59PM Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at BMO Capital

Apr 15, 2019 06:50AM Alnylam Pharmaceuticals (ALNY) PT Raised to $126 at BMO Capital; Sees 100% Probability of Givosiran Approval

Apr 8, 2019 12:43PM Alnylam Pharmaceuticals (ALNY) PT Raised to $119 at BMO Capital on Regeneron Deal

Feb 8, 2019 07:50AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $106 at BMO Capital

Nov 8, 2018 08:56AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at BMO Capital

Aug 13, 2018 06:35AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data

Feb 8, 2018 12:41PM Alnylam Pharmaceuticals (ALNY) PT Lowered to $160 at BMO Capital

Dec 7, 2017 04:00PM Alnylam to Webcast Presentation at BMO Capital Markets Prescriptions for Success Healthcare Conference

Sep 21, 2017 03:40PM Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario

Sep 8, 2017 08:51AM Alnylam Pharmaceuticals (ALNY) PT Lowered to $99 at BMO Capital; Fitusiran Delay to 'Reduce Probability of Success'

Sep 7, 2017 10:10AM BMO Capital Maintains Rating, PT on Alnylam (ALNY) Despite Fatal Thrombotic Event

Sep 6, 2017 06:26AM Ionis Pharma (IONS): Patisiran APOLLO Data Should Have Only Modest Impact - BMO

Apr 17, 2017 12:29PM BMO Capital Reiterates Outperform Rating and $73 PT on Alnylam Pharmaceuticals (ALNY); 'Emicizumab Data Does Not Dampen Our Fitusiran Enthusiasm'

Apr 17, 2017 06:35AM BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform; Revusiran Overhang Clouding Strong Pipeline

Oct 6, 2016 06:29AM BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure

Aug 3, 2016 10:41AM Notable Analyst Rating Changes 8/3: (ZNGA) (NMBL) (AVD) Upgraded; (CSIQ) (EQR) (EMR) Downgraded

Feb 13, 2015 09:19AM Pre-Open Stock Movers 02/13: (KING) (CYBR) (CYTK) Higher; (MX) (KN) (ZNGA) Lower (more...)

Jan 14, 2014 09:28AM Pre-Open Stock Movers 1/14: (OPTT) (TC) (ISRG) Higher; (GME) (SSYS) (BGFV) Lower (more...)

Oct 4, 2012 04:09PM Regulus Therapeutics (RGLS) IPO Closes 5% Higher

Jul 16, 2012 03:25PM Notable 52-Week Highs and Lows of the Day 07/16: (ALNY) (AUTH) (V) High; (ANR) (GMCR) (GDI) Low

Jul 16, 2012 12:56PM Unusual 11 Mid-Day Movers 07/16: (ALNY) (PRX) (CONM) Higher; (ANR) (AUTH) (VISN) Lower

Jul 16, 2012 10:21AM Morning Movers 07/16: (PRX) (ALNY) (CONM) Higher; (ANR) (GDI) Lower